S

D

SCHADENDORF , Dirk

Last name: SCHADENDORF

First name: Dirk

March 4, 2024 (v1)

Publication

Metadata-only

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Weber, Jeffrey S. Schadendorf, Dirk Del Vecchio, Michele

PURPOSE Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or IV melanoma. PATIENTS AND METHODS In this randomized, double-blind, phase III trial, 1,833 patients...

Uploaded on: March 6, 2024
March 5, 2024 (v1)

Publication

Metadata-only

Adjuvant pembrolizumab versus placebo in resected high risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study

Khattak, Muhammad A. Luke, Jason J. Long, Georgina V.

Abstract Background: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 study. Health-related quality of life (HRQoL) results are reported. Methods: Patients were randomly assigned 1:1 to pembrolizumab 200 mg (2 mg/kg, patients 12 to <18...

Uploaded on: March 7, 2024